CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 107 enrolled
Drug / intervention
Fludrocortisone 0.1 Milligrams (mg) +1 moredrug
Likely dose
Fludrocortisone 0.1 Milligrams (mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04351126
NCT04351126Phase 2Completed
CompareCT.gov

Pathophysiology and Nature of Ovarian Hyperstimulation Syndrome (OHSS) as a Clinical Entity Could be Fully Explained and Effectively Managed as a State of Defective Mineralocorticoid Response

Ganin Fertility Center·interventional·Posted Apr 17, 2020·Updated Apr 17, 2020

In Brief

A Phase 2 clinical trial evaluating Fludrocortisone 0.1 Milligrams (mg) and Bromocriptine for Ovarian Hyperstimulation Syndrome. Completed, enrolled 107 participants across 1 site.

Detailed Summary

lines of evidence that support nature of ovarian hyperstimulation syndrome (OHSS) as "defective mineralocorticoid response" are cited, our hypothesis is tested clinically in both prophylaxis against and treatment of OHSS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Hyperstimulation Syndrome
CountriesEgypt
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 17, 2020
Enrollment StartApr 1, 2019
Primary CompletionFeb 25, 2020
Study CompletionFeb 29, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.2 years ago

Interventions

Fludrocortisone 0.1 Milligrams (mg)drug

0.2-0.6 mg/day of fludrocortisone is prescribed

Bromocriptinedrug

2.5 mg prescribed Vaginally twice daily